Parenteral Drugs (India) (NSE:PDPL) Total Long-Term Assets: ₹4,170.98 Mil (As of Mar. 2022)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) Total Long-Term Assets?

Parenteral Drugs (India) NSE:PDPL 4 Total Long-Term Assets is ₹4,170.98 Mil as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Parenteral Drugs (India)'s Total Long-Term Assets for the quarter that ended in Mar. 2022 was ₹4,170.98 Mil.

Parenteral Drugs (India) Total Long-Term Assets Related Terms

Parenteral Drugs (India) Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Total Long-Term Assets Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,913.74 4,732.61 4,843.86 5,001.31 4,170.98

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,001.31 0.00 5,099.86 0.00 4,170.98
NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of ₹4,170.98 Mil mean?
Parenteral Drugs (India) (NSE:PDPL) has a Total Long-Term Assets of ₹4,170.98 Mil as of Mar. 2022. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Total Long-Term Assets too high?
Parenteral Drugs (India)'s current Total Long-Term Assets is ₹4,170.98 Mil. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Total Long-Term Assets compare to ZTS and CTLT?
Parenteral Drugs (India)'s Total Long-Term Assets of ₹4,170.98 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current Total Long-Term Assets is ₹4,170.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Total Long-Term Assets of ₹4,170.98 Mil. The current Total Long-Term Assets is ₹4,170.98 Mil. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Total Long-Term Assets is ₹4,170.98 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price